Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) has been moving up since Tuesday. Yesterday, the stock added the next 3.77% 
to its price, while its traded volume remained substantially high.
There are two factors related to the gain – news and promotions. On Dec 13, Idera reported that it presented new data in preclinical models of lymphoma on its IMO-4200 at the American Society for Hematology meeting.
Apparently, the positive statements on the new data released pumped up IDRA stock price at once, though the gain was immediately ensured by promotions.
The campaign was held on the same day when IDRA got promoted by five different promoters to fuel up the climb. And obviously, it worked out. The stock price got even higher yesterday. Now the question is what happens today?
Idera Pharmaceuticals works on creating immune modulatory drug candidates through applying its Toll-like Receptor drug discovery platform. Over the past few days, a significant amount of the company’s shares of common stock has been acquired by different members of Idera’s stuff with no particular reason.[BANNER]
The latest 10-Q of the company shows an increasing net loss, accumulated deficit and poor revenues, which cannot support Idera’s operations. Besides, the company expects more losses to come and states that it is depending heavily on the development of its drug candidates and on numerous risk factors that are beyond its control.
In other words, if Idera doesn’t successfully develop and commercialize its drug candidates, or experiences significant delays in doing so, its business may be materially harmed.
